Effect of vasopressin V1b receptor antagonist, SSR149415, on anxiety-like behavior and Lewis lung carcinoma metastasis in mice

Experimental Oncology

Volumn 33, Issue 3, 2011, Pages 126-129

  Amikishieva, A V ^a   Ilnitskaya, S I ^a   Nikolin, V P ^a   Popova, N A ^a  

^a INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

Author keywords

Anxiety; Lewis lung carcinoma; Metastasis; SSR149415; Vasopressin receptor

Indexed keywords

NELIVAPTAN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EMOTION; LEWIS CARCINOMA; LOCOMOTION; LUNG METASTASIS; MALE; MAZE TEST; MOUSE; NONHUMAN; OPEN FIELD TEST; SOCIAL INTERACTION; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; CARCINOMA, LEWIS LUNG; EMOTIONS; INDOLES; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEOPLASM METASTASIS; PYRROLIDINES; RECEPTORS, VASOPRESSIN;

EID: 80053408463     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Amikishieva AV, Ilnitskaya SI, Popova NA, et al. Vasopressin as stimulator of the cancerous growth metastases. Eur J Neuropsychopharmacol 2009; 19: 350.
2. Bhattacharya SK, Bhattacharya A, Chakrabarti A. Anxiogenic activity of intraventricularly administered argininevasopressin in the rat. Biogen Amine 1998; 14: 367-85. (Pubitemid 28446111)
3. Bukhtoyarov OV, Arkhangelsky AE. Psychogenic death in oncology: validation, pathogenesis, development patterns and prophylactic potential. Vopr Onkol 2006; 52: 708-15 (In Russian).
4. De Bellis MD, Gold PW, Geracioti TD, et al. Association of fluoxetine treatment with reductions in CSF concentrations of corticotrophin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry 1993; 150: 656-7. (Pubitemid 23109940)
5. Engin E, Treit D. Dissociation of the anxiolytic-like effects of Avp1a and Avp1b receptor antagonists in the dorsal and ventral hippocampus. Neuropeptides 2008; 42: 411-21.
6. File SE, Seth P. A review of 25 years of the social interaction test. Eur J Pharmacol 2003; 463: 35-53. (Pubitemid 36205071)
7. Griebel G, Simiand J, Serradeil-Le Gal C, et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. PNAS 2002; 99: 6370-5. (Pubitemid 34493318)
8. Hernando F, Schoots O, Lolait SJ, et al. Immunihistochemical localization of the vasopressin V1b receptor in the rat brain bad pituitary gland: anatomical support for its involvement in the central effects of vasopressin. Endocrinol 2001; 142: 1659-68. (Pubitemid 32299697)
9. Kaledin VI, Ilnitskaya SI, Nikolin VP, et al. Limiting effect of diazepam on Lewis lung carcinoma metastasis in anxious male mice. Exp Oncol 2009; 31: 62-4.
10. Kaledin VI, Tenditnik MV, Nikolin VP, et al. Effect of psychoemotional state on growth and metastasis of Lewis tumor in mice. Dokl Akad Nauk 2006; 406: 272-4 (In Russian).
11. Kalsbeek A, Palm IF, Buijs RM. Central vasopressin systems and steroid hormones. Prog Brain Res 2002; 139: 57-73. (Pubitemid 35460880)
12. Keck ME, Welt T, Muller MB, et al. Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacol 2003; 28: 235-43.
13. Kovacs KJ. Functional neuroanatomy of the parvocellular vasopressinergic system: transcriptional responses to stress and glucocorticoid feedback. Prog Brain Res 1998; 119: 31-43. (Pubitemid 29099962)
14. Kovacs KJ, Foldes A, Sawchenko PE. Glucocorticoid negative feedback selectively targets vasopressin transcription in parvocellular neurosecretory neurons. J Neurosci 2000; 20: 3843-52. (Pubitemid 30266245)
15. Kudryavtseva NN. Experience of defeat decreases the behavioral reactivity to conspecifics in the partition test. Behav Proc 1994; 32: 297-304.
16. Kudryavtseva NN, Tenditnik MV, Nikolin VP, et al. The influence of psychoemotional status on metastasis of Lewis lung carcinoma and hepatocarcinoma-29 in mice of C57Bl/6J and CBA/Lac strains. Exp Oncol 2007; 29: 35-8. (Pubitemid 46713477)
17. Landgraf R, Gerstberger R, Montkowski A, et al. V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. J Neurosci 1995; 15: 4250-8.
18. Landgraf R, Wigger A. High vs low anxiety-related behavior rats: an animal model of extremes in trait anxiety. Behav Genet 2002; 32: 301-14. (Pubitemid 35192992)
19. Mlynarek M, Zelena D, Bagdy G, et al. Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats. Horm and Behav 2007; 51: 395-405. (Pubitemid 46365691)
20. Ostrowski NL, Lolait SJ, Young WS. Cellular localization of vasopressin V1a receptor messenger ribonucleic acid in adult male rat brain, pineal, and brain vasculature. Endocrinol 1994; 135: 1511-28. (Pubitemid 24307529)
21. Rene P, De Keyzer Y. The vasopressin receptor of corticotroph pituitary cells. Prog Brain Res 2002; 139: 345-57. (Pubitemid 35460901)
22. Riley V. Psychoneuroendocrine influence on immunocmpetence and neoplasia. Science 1981; 212: 1100-9.
23. Ring RH. The central vasopressinergic system: examining the opportunities for psychiatric drug development. Curr Pharm Des 2005; 11: 205-25. (Pubitemid 40089841)
24. Rodgers RG, Cole JC. The elevated plus-maze: pharmacology, methodology and ethology. In: Cooper SJ, Hendrie CA, eds. Ethology and Psychopharmacology. New York: John Wiley & Son Ltd, 1994: 9-44.
25. Volodin BYu. Potentialities of psychotherapy in oncological care. Rus J Oncol 2009; 1: 43-5 (In Russian).